Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works

Myeloid-derived-suppressor cells as regulators of the immune system

Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · see citing works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508 · see citing works

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · see citing works

Exosomes: composition, biogenesis and function

Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature reviews. Immunology · doi:10.1038/nri855 · Cited by 5,355 · see citing works

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · see citing works

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783 · see citing works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · see citing works

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · see citing works

Tumour-educated macrophages promote tumour progression and metastasis

Pollard, J. W. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1256 · Cited by 3,365 · see citing works

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228 · see citing works

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110 · see citing works

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · see citing works

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503 · see citing works

Ido expression by dendritic cells: tolerance and tryptophan catabolism

Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341 · see citing works

The immune contexture in cancer prognosis and treatment

Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263 · see citing works

PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity

Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247 · see citing works

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,072 · see citing works

The tumor microenvironment at a glance

Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857 · see citing works

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i> -Mutant Lung Adenocarcinoma

Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · see citing works

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

Shi, Y., Au, J. S. K., Thongprasert, S., Srinivasan, S., Tsai, C., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G. H., & Yang, P. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,554 · see citing works

Classifying Cancers Based on T-cell Infiltration and PD-L1

Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,412 · see citing works

Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates

Simoni, Y., Becht, E., Fehlings, M., Loh, C. Y., Koo, S.-L., Teng, K. W. W., Yeong, J. P. S., Nahar, R., Zhang, T., Kared, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0130-2 · Cited by 1,370 · see citing works

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

Mazières, J., Drilon, A. E. D. C., Lusque, A., Mhanna, L., Cortot, A. B., Mezquita, L., Thai, A. A., Mascaux, C., Couraud, S., Veillon, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz167 · Cited by 1,359 · see citing works

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,342 · see citing works

VEGF targets the tumour cell

Goel, H. L., & Mercurio, A. M. (2013) · Nature reviews. Cancer · doi:10.1038/nrc3627 · Cited by 1,258 · see citing works

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis

Gainor, J. F., Shaw, A. T., Sequist, L. V. D., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L. E., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,256 · see citing works

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,237 · see citing works

NK cells and cancer: you can teach innate cells new tricks

Morvan, M. G., & Lanier, L. L. (2015) · Nature reviews. Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,159 · see citing works

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

Li, C., Lim, S., Xia, W., Lee, H., Chan, L.-C., Kuo, C., Khoo, K., Chang, S.-S., Cha, J., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,100 · see citing works

IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation

Ouyang, W., & O’Garra, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.020 · Cited by 1,084 · see citing works

PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer

Kamada, T., Togashi, Y., Tay, C., Ha, D., Sasaki, A., Nakamura, Y., Sato, E., Fukuoka, S., Tada, Y., Tanaka, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1822001116 · Cited by 1,006 · see citing works

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

Hellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962 · see citing works

Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Dong, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Xie, Z., Liu, S.-Y., Tu, H.-Y., Chen, H.-J., Sun, Y.-L., Zhou, Q., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2554 · Cited by 959 · see citing works

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., Moro‐Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 953 · see citing works

Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

Skoulidis, F., Byers, L. A., Diao, L., Papadimitrakopoulou, V. A., Tong, P., Izzo, J., Behrens, C., Kadara, H., Parra, E. R., Canales, J. R., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1236 · Cited by 936 · see citing works

Regulation of human NK-cell cytokine and chemokine production by target cell recognition

Fauriat, C., Long, E. O., Ljunggren, H., & Bryceson, Y. T. (2009) · Blood · doi:10.1182/blood-2009-08-238469 · Cited by 894 · see citing works

Dendritic-Cell-Based Therapeutic Cancer Vaccines

Palucka, K., & Banchereau, J. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.004 · Cited by 869 · see citing works

Targeting immunosuppressive adenosine in cancer

Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature reviews. Cancer · doi:10.1038/nrc.2017.86 · Cited by 852 · see citing works

Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis

Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839 · see citing works

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831 · see citing works

The “cancer immunogram”

Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016) · Science · doi:10.1126/science.aaf2834 · Cited by 748 · see citing works

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

Gettinger, S. N., Horn, L., Jackman, D. M., Spigel, D. R., Antonia, S. J., Hellmann, M. D., Powderly, J. D., Heist, R. S., Sequist, L. V. D., Smith, D. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0412 · Cited by 740 · see citing works

A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer

Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738 · see citing works

The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer

Naugler, W. E., & Karin, M. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.12.007 · Cited by 730 · see citing works

Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy

Ferrara, R., Mezquita, L., Texier, M., Lahmar, J., Audigier-Valette, C., Tessonnier, L., Mazieres, J., Zalcman, G., Brosseau, S., Le Moulec, S., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3676 · Cited by 720 · see citing works

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

Chen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., Zhang, Y., He, X., Zhou, T., Qin, T., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000500 · Cited by 670 · see citing works

Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR

Al-Nedawi, K. N. I., Meehan, B., Kerbel, R. S., ALLISON, A. C., & Rak, J. W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804543106 · Cited by 666 · see citing works

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

Azuma, K., Ota, K., Kawahara, A., Hattori, S., Iwama, E., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., Kage, M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu242 · Cited by 643 · see citing works

Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.

Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., Placido, S. D., Bianco, A. R., & Tortora, G. (2001) · PubMed · Cited by 643 · see citing works

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis

Lee, C. K., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R. S., Gralla, R. J., Mok, T., & Yang, J. C.-H. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4427 · Cited by 598 · see citing works

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC

Lisberg, A., Cummings, A., Goldman, J. W., Bornazyan, K., Reese, N., Wang, T., Coluzzi, P., Ledezma, B., Mendenhall, M., Hunt, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.035 · Cited by 580 · see citing works

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30144-x · Cited by 568 · see citing works

Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis

Zhang, H., Deng, T., Liu, R., Bai, M., Zhou, L., Wang, X., Li, S., Wang, X., Yang, H., Li, J., et al. (2017) · Nature Communications · doi:10.1038/ncomms15016 · Cited by 561 · see citing works

IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation

Park, S.-J., Nakagawa, T., Kitamura, H., Atsumi, T., Kamon, H., Sawa, S.-I., Kamimura, D., Ueda, N., Iwakura, Y., Ishihara, K., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.6.3844 · Cited by 519 · see citing works

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Gettinger, S., Rizvi, N. A., Chow, L. Q., Borghaei, H., Brahmer, J., Ready, N., Gerber, D. E., Shepherd, F. A., Antonia, S., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9929 · Cited by 501 · see citing works

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner

Holmgaard, R., Zamarin, D., Li, Y., Gasmi, B., Munn, D. H., Allison, J. P., Merghoub, T., & Wolchok, J. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.077 · Cited by 483 · see citing works

Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR

Yokogami, K., Wakisaka, S., Avruch, J., & Reeves, S. A. (2000) · Current Biology · doi:10.1016/s0960-9822(99)00268-7 · Cited by 468 · see citing works

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease

Ohashi, K., Maruvka, Y. E., Michor, F., & Pao, W. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3912 · Cited by 467 · see citing works

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

Sanmamed, M. F., Perez‐Gracia, J. L., Schalper, K. A., Fusco, J. P., González, Á., Rodriguez-Ruiz, M. E., Oñate, C., Perez, G., Alfaro, C., Martín‐Algarra, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx190 · Cited by 458 · see citing works

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Rizvi, N. A., Hellmann, M. D., Brahmer, J. R., Juergens, R. A., Borghaei, H., Gettinger, S. N., Chow, L. Q. M., Gerber, D. E., Laurie, S. A., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9861 · Cited by 446 · see citing works

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356145 · Cited by 440 · see citing works

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Oxnard, G. R., Yang, J. C.-H., Yu, H., Kim, S.-W., Saka, H., Horn, L., Goto, K., Ohe, Y., Mann, H., Thress, K. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.013 · Cited by 438 · see citing works

Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor

Zaiss, D. M. W., van Loosdregt, J., Gorlani, A., Bekker, C. P. J., Gröne, A., Sibilia, M. C., Henegouwen, P. M. P. V. B. E., Roovers, R. C., Coffer, P. J., & Sijts, A. J. A. M. (2013) · Immunity · doi:10.1016/j.immuni.2012.09.023 · Cited by 418 · see citing works

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

Schoenfeld, A. J., Arbour, K. C., Rizvi, H., Iqbal, A. N., Gadgeel, S. M., Girshman, J., Kris, M. G., Riely, G. J., Yu, H. A., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz077 · Cited by 406 · see citing works

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Peters, S., Gettinger, S. N., Johnson, M. L., Janne, P. A., Garassino, M. C., Christoph, D. C., Toh, C., Rizvi, N. A., Chaft, J. E., Carcereny, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9476 · Cited by 400 · see citing works

Tumor neoantigens: from basic research to clinical applications

Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 386 · see citing works

CD39 Expression Identifies Terminally Exhausted CD8+ T Cells

Gupta, P., Godec, J., Wolski, D., Adland, E., Yates, K. B., Pauken, K. E., Cosgrove, C., Ledderose, C., JUNGER, W. G., Robson, S. C., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005177 · Cited by 384 · see citing works

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

Zhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362 · see citing works

Hyperprogressive disease: recognizing a novel pattern to improve patient management

Champiat, S., Ferrara, R., Massard, C., Besse, B., Marabelle, A., Soria, J., & Ferté, C. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0111-2 · Cited by 360 · see citing works

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer

Brambilla, E. M., Teuff, G. L., Marguet, S., Lantuéjoul, S., Dunant, A., Graziano, S. L., Pirker, R., Douillard, J.-Y., Chevalier, T. L., Filipits, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0970 · Cited by 351 · see citing works

Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

Le, X., Nilsson, M. B., Goldman, J. W., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt‐Moller, B., Wolff, K., Visseren‐Grul, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.006 · Cited by 349 · see citing works

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

Schoenfeld, A. J., Rizvi, H., Bandlamudi, C., Sauter, J. L., Travis, W. D., Rekhtman, N., Plodkowski, A. J., Pérez-Johnston, R., Sawan, P., Beras, A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.065 · Cited by 324 · see citing works

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer

Castellanos, E. H., Feld, E., & Horn, L. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.014 · Cited by 319 · see citing works

EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer

Oshima, Y., Tanimoto, T., Yuji, K., & Tojo, A. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4526 · Cited by 313 · see citing works

Targeting Cancer-Derived Adenosine:New Therapeutic Approaches

Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 312 · see citing works

Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy

Chowell, D., Krishna, C., Pierini, F., Makarov, V., Rizvi, N. A., Kuo, F., Morris, L. G. T., Riaz, N., Lenz, T. L., & Chan, T. A.-T. (2019) · Nature Medicine · doi:10.1038/s41591-019-0639-4 · Cited by 309 · see citing works

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Haratani, K., Hayashi, H., Tanaka, T., Kaneda, H., Togashi, Y., Sakai, K., Hayashi, K., Tomida, S., Chiba, Y., Yonesaka, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx183 · Cited by 295 · see citing works

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer

Sugiyama, E., Togashi, Y., Takeuchi, Y., Shinya, S., Tada, Y., Kataoka, K., Tane, K., Sato, E., Ishii, G., Goto, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aav3937 · Cited by 292 · see citing works

Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration

Oweida, A. J., Hararah, M. K., Phan, A. V., Binder, D. C., Bhatia, S., Lennon, S., Bukkapatnam, S., Court, B. V., Uyanga, N., Darragh, L. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1038 · Cited by 274 · see citing works

Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations

Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 263 · see citing works

PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

Naing, A., Infante, J. R., Papadopoulos, K. P., Chan, I. H., Shen, C., Ratti, N. P., Rojo, B., Autio, K. A., Wong, D. J. L., Patel, M. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.10.007 · Cited by 255 · see citing works

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer

Isomoto, K., Haratani, K., Hayashi, H., Shimizu, S., Tomida, S., Niwa, T., Yokoyama, T., Fukuda, Y., Chiba, Y., Kato, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2027 · Cited by 250 · see citing works

Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations

He, D., Wang, D., Lü, P., Yang, N., Xue, Z., Zhu, X., Zhang, P., & Fan, G. (2020) · Oncogene · doi:10.1038/s41388-020-01528-0 · Cited by 242 · see citing works

Phenotype, development, and biological function of myeloid-derived suppressor cells

Zhao, Y., Wu, T., Shao, S., Shi, B., & Zhao, Y. X. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1004983 · Cited by 220 · see citing works

Comprehensive T cell repertoire characterization of non-small cell lung cancer

Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14273-0 · Cited by 220 · see citing works

EGFR and NF-κB: partners in cancer

Shostak, K., & Chariot, A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.001 · Cited by 218 · see citing works

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

Yang, J. C.-H., Shepherd, F. A., Kim, D.-W., Lee, G.-W., Lee, J. S., Chang, G.-C., Lee, S. S., Wei, Y.-F., Lee, Y. G., Laus, G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.001 · Cited by 210 · see citing works

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)

Hsu, P., Jablons, D. M., Yang, C., & You, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153821 · Cited by 207 · see citing works

Higher levels of GATA3 predict better survival in women with breast cancer

Yoon, N. K., Maresh, E. L., Shen, D., Elshimali, Y., Apple, S. K., Horvath, S., Mah, V. H., Bose, S., Chia, D., Chang, H. R., et al. (2010) · Human Pathology · doi:10.1016/j.humpath.2010.06.010 · Cited by 195 · see citing works

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

Gettinger, S. N., Choi, J., Mani, N. L., Sanmamed, M. F., Datar, I. J., Sowell, R., Du, V. Y., Kaftan, E. J., Goldberg, S. B., Dong, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05032-8 · Cited by 186 · see citing works

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

Yang, J. C., Gadgeel, S. M., Sequist, L. V. D., Wu, C.-L., Papadimitrakopoulou, V. A., Su, W., Fiore, J., Saraf, S., Raftopoulos, H., & Patnaik, A. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.028 · Cited by 184 · see citing works

Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma

Takada, K., Okamoto, T., Shoji, F., Shimokawa, M., Akamine, T., Takamori, S., Katsura, M., Suzuki, Y., Fujishita, T., Toyokawa, G., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.06.006 · Cited by 183 · see citing works

TGF ‐β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK /Sp1 signaling pathways

Zhao, Y., Ma, J., Fan, Y., Wang, Z., Tian, R., Ji, W., Zhang, F., & Niu, R. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12162 · Cited by 175 · see citing works

Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes

Pollack, B. P., Sapkota, B., & Cartee, T. V. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3283 · Cited by 169 · see citing works

A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients

Rodríguez, P. C., Popa, X., Martínez, O., Mendoza, S., Santiesteban, E. R., Crespo, T., Amador, R. M., Fleytas, R., Acosta, S. C., Otero, Y., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0855 · Cited by 169 · see citing works

EGFR‐targeted therapy alters the tumor microenvironment in EGFR‐driven lung tumors: Implications for combination therapies

Jia, Y., Li, X., Jiang, T., Zhao, S., Zhao, C., Zhang, L., Liu, X., Shi, J., Qiao, M., Luo, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32191 · Cited by 164 · see citing works

Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non–small-cell lung cancer: The global, multicenter EXPRESS study

Dietel, M., Савелов, Н. А., Salanova, R., Micke, P., Bigras, G., Hida, T., López, J. R. A., Skov, B. G., Hutarew, G., Sua, L. F., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.012 · Cited by 159 · see citing works

Epidermal Growth Factor Receptor-Containing Exosomes Induce Tumor-Specific Regulatory T Cells

Huang, S., Li, Y., Zhang, J., Rong, J., & Ye, S. (2013) · Cancer Investigation · doi:10.3109/07357907.2013.789905 · Cited by 154 · see citing works

Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions

Soo, R. A., Lim, S. M., Syn, N. L. X., Teng, R. S. Y., Soong, R., Mok, T. S. K., & Cho, B. C. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.009 · Cited by 153 · see citing works

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma

Hogan, S. A., Courtier, A., Cheng, P. F., Jaberg-Bentele, N. F., Goldinger, S. M., Manuel, M., Perez, S., Plantier, N., Mouret, J.-F., Nguyen‐Kim, T. D. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0136 · Cited by 153 · see citing works

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB

Lin, K., Cheng, J., Yang, T., Li, Y., & Zhu, B. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.05.030 · Cited by 152 · see citing works

EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice

Gahr, S., Stoehr, R., Geissinger, E., Ficker, J. H., Brueckl, W. M., Gschwendtner, A., Gattenloehner, S., Fuchs, F. S., Schulz, C. K. J., Rieker, R. J., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.511 · Cited by 149 · see citing works

M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer

Cao, L., Che, X., Qiu, X.-S., Li, Z., Yang, B., Wang, S., Hou, K., Fan, Y., Qu, X., & Liu, Y. (2019) · Cancer Management and Research · doi:10.2147/cmar.s199832 · Cited by 144 · see citing works

Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers

Jiang, T., Xu, X., Qiao, M., Li, X., Zhao, C., Zhou, F., Gao, G., Wu, F., Chen, X., Su, C., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4073-7 · Cited by 141 · see citing works

Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors

Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133 · see citing works

Targeting γδ T Lymphocytes for Cancer Immunotherapy: From Novel Mechanistic Insight to Clinical Application

Gomes, A. Q., Martins, D., & Silva‐Santos, B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-3236 · Cited by 130 · see citing works

PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations

Ji, M., Liu, Y., Li, Q., Li, X., Ning, Z., Zhao, W., Shi, H., Jiang, J., & Wu, C. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1156256 · Cited by 126 · see citing works

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target

Le, X., Negrao, M. V., Reuben, A., Federico, L., Diao, L., McGrail, D. J., Nilsson, M. B., Robichaux, J. P., Guijarro, I., Patel, S. A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.010 · Cited by 126 · see citing works

Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial

Naing, A., Wong, D. J. L., Infante, J. R., Korn, W. M., Aljumaily, R. M., Papadopoulos, K. P., Autio, K. A., Pant, S., Bauer, T. M., Drakaki, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30514-5 · Cited by 122 · see citing works

Potential mechanism of interleukin‐8 production from lung cancer cells: An involvement of EGF–EGFR–PI3K–Akt–Erk pathway

Zhang, Y., Wang, L., Zhang, M., Jin, M., Bai, C., & Wang, X. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22722 · Cited by 113 · see citing works

PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung Cancer

Negrao, M. V., Lam, V. K. L., Reuben, A., Rubin, M. L., Landry, L. L., Roarty, E. B., Rinsurongkawong, W., Lewis, J., Roth, J. A., Swisher, S. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.008 · Cited by 112 · see citing works

Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations

Toki, M. I., Mani, N. L., Smithy, J. W., Liu, Y., Altan, M., Wasserman, B. E., Tuktamyshov, R., Schalper, K. A., Syrigos, K. N., & Rimm, D. L. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.012 · Cited by 111 · see citing works

Harnessing γδ T cells in anticancer immunotherapy

Hannani, D., Ma, Y., Yamazaki, T., Déchanet‐Merville, J., Kroemer, G., & Zitvogel, L. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.01.006 · Cited by 110 · see citing works

Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma

Jiang, T., Shi, J., Dong, Z., Hou, L., Zhao, C., Li, X., Mao, B., Zhu, W., Guo, X., Zhang, H., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0762-1 · Cited by 107 · see citing works

Oncogenic KRAS‐induced interleukin‐8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non‐small cell lung cancer

Sunaga, N., Imai, H., Shimizu, K., Shames, D. S., Kakegawa, S., Girard, L., Sato, M., Kaira, K., Ishizuka, T., Gazdar, A. F., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26164 · Cited by 99 · see citing works

TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer

Gong, K., Guo, G., Gerber, D. E., Gao, B., Peyton, M., Huang, C., Minna, J. D., Hatanpaa, K. J., Kernstine, K., Cai, L., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96148 · Cited by 98 · see citing works

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer

Lamberti, G., Spurr, L. F., Li, Y. Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L. M., Meyerson, M. M., Cherniack, A. D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.017 · Cited by 98 · see citing works

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor

Kim, Y., Kim, C. H., Lee, H. Y., Lee, S., Kim, H. S., Lee, S., Cha, H., Hong, S., Kim, K., Seo, S. W., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.033 · Cited by 97 · see citing works

Tumor‐associated macrophages correlate with response to epidermal growth factor receptor‐tyrosine kinase inhibitors in advanced non‐small cell lung cancer

Chung, F., Lee, K., Wang, C., Heh, C., Chan, Y., Chen, H., Kuo, C.-H. S., Feng, P., Lin, T., Wang, C., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27403 · Cited by 96 · see citing works

Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells

Xu, L., Nilsson, M. B., Saintigny, P., Cascone, T., Herynk, M. H., Du, Z., Nikolinakos, P. G., Yang, Y., Prudkin, L., Liu, D., et al. (2010) · Oncogene · doi:10.1038/onc.2010.16 · Cited by 93 · see citing works

MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

Koh, J., Kim, Y., Lee, K. Y., Hur, J. Y., Kim, M. S., Kim, B., Cho, H. J., Lee, Y. C., Bae, Y. H., Ku, B. M., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048534 · Cited by 91 · see citing works

Amphiregulin expression in human mast cells and its effect on the primary human lung fibroblasts

Wang, S., Oh, C. K., Cho, S., Hu, G., Martin, R. E., Demissie-Sanders, S., Li, K., Moyle, M., & Yao, Z. (2005) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.11.037 · Cited by 90 · see citing works

Clinical Development and Perspectives of CIMAvax EGF, Cuban Vaccine for Non-small-cell Lung Cancer Therapy

Rodríguez, P. C., Rodríguez, G., González, G., & Lage, A. (2010) · MEDICC Review · doi:10.37757/mr2010.v12.n1.4 · Cited by 90 · see citing works

CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients

Saavedra, D., & Crombet, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00269 · Cited by 90 · see citing works

PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy

Chen, K., Cheng, G., Zhang, F., Zhu, G., Xu, Y., Yu, X., Huang, Z., & Fan, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.010 · Cited by 89 · see citing works

A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing

Lizotte, P. H., Hong, R.-L., Luster, T. A., Cavanaugh, M. E., Taus, L. J., Wang, S., Dhaneshwar, A., Mayman, N., Yang, A., Kulkarni, M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0193 · Cited by 88 · see citing works

NK cell-based therapeutics for lung cancer

Pockley, A. G., Vaupel, P. W., & Multhoff, G. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1688298 · Cited by 86 · see citing works

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients

Garassino, M. C., Gelibter, A. J., Grossi, F., Chiari, R., Parra, H. J. S., Cascinu, S., Cognetti, F., Turci, D., Blasi, L., Bengala, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.025 · Cited by 85 · see citing works

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H

Gubens, M. A., Sequist, L. V. D., Stevenson, J. P., Powell, S. F., Villaruz, L. C., Gadgeel, S. M., Langer, C. J., Patnaik, A., Borghaei, H., Jalal, S. I., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.015 · Cited by 82 · see citing works

HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer

Jackson, A. L., Zhou, B. R., & Kim, W. Y. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.511617 · Cited by 79 · see citing works

Dendritic cell-based therapeutic cancer vaccines: past, present and future

Ahmed, M. S., & Bae, Y. (2014) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2014.3.2.113 · Cited by 73 · see citing works

Predictive biomarkers for hyper-progression (HP) in response to immune checkpoint inhibitors (ICI) – analysis of somatic alterations (SAs)

Singavi, A. K., Menon, S., Kilari, D., Alqwasmi, A., Ritch, P. S., Thomas, J. P., Martin, A. L., Oxencis, C. J., Ali, S. S., & George, B. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx376.006 · Cited by 73 · see citing works

EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells

Yu, S., Sha, H., Qin, X., Chen, Y., Li, X., Shi, M., & Feng, J. (2020) · Oncogene · doi:10.1038/s41388-020-1182-y · Cited by 70 · see citing works

Immune regulation and cytotoxic T cell activation of IL-10 agonists – Preclinical and clinical experience

Oft, M. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101325 · Cited by 69 · see citing works

Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations

Mansuet‐Lupo, A., Alifano, M., Pécuchet, N., Biton, J., Becht, É., Goc, J., Germain, C., Ouakrim, H., Régnard, J., Cremer, I., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-2031oc · Cited by 67 · see citing works

Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway

Luo, Q., Gu, Y., Zheng, W., Wu, X., Gong, F., Gu, L., Sun, Y., & Xu, Q. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.12.011 · Cited by 60 · see citing works

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities

Santaniello, A., Napolitano, F., Servetto, A., Placido, P. D., Silvestris, N., Bianco, C., Formisano, L., & Bianco, R. (2019) · Cancers · doi:10.3390/cancers11101419 · Cited by 60 · see citing works

Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing

Jang, M., Yew, P., Hasegawa, K., Ikeda, Y., Fujiwara, K., Fleming, G. F., Nakamura, Y., & Park, J.-H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1030561 · Cited by 58 · see citing works

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

Watanabe, S., Hayashi, H., Haratani, K., Shimizu, S., Tanizaki, J., Sakai, K., Kawakami, H., Yonesaka, K., Tsurutani, J., Togashi, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13860 · Cited by 57 · see citing works

Prognostic value of PD ‐L1 expression in combination with CD 8 + TIL s density in patients with surgically resected non‐small cell lung cancer

Yang, H. J., Shi, J., Lin, D., Li, X., Zhao, C., Wang, Q., Zhang, L., Jiang, T., Zhao, S., Liu, X., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1243 · Cited by 50 · see citing works

PD‐L1 expression in ROS1‐rearranged non‐small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1

Lee, J. M., Park, C. K., Yoon, H. K., Jo, Y., Woo, I. S., Kim, H. R., Kim, S. Y., & Kim, T. J. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12917 · Cited by 48 · see citing works

Increased CD73 and reduced IFNG signature expression in relation to response rates to anti-PD-1(L1) therapies in EGFR-mutant NSCLC.

Streicher, K. L., Higgs, B. W., Wu, S., Coffman, K. T., Damera, G., Durham, N., Greenlees, L. M., Lazdun, Y., Li, C., Cooper, Z. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.11505 · Cited by 45 · see citing works

441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC

Ma, B. B. Y., Rudin, C. M., Cervantes, A. M. R., Dowlati, A., Costa, D. B., Schmid, P., Heist, R. S., Villaflor, V. M., Sarkar, I., Huseni, M. A., et al. (2016) · Annals of Oncology · doi:10.1016/s0923-7534(21)00599-8 · Cited by 41 · see citing works

Hypofractionated EGFR tyrosine kinase inhibitor limits tumor relapse through triggering innate and adaptive immunity

Liu, Z., Han, C., Dong, C., Shen, A., Hsu, E. J., Ren, Z., Lu, C., Liu, L., Zhang, A., Timmerman, C., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aav6473 · Cited by 41 · see citing works

Nivolumab in non-small-cell lung cancer with EGFR mutation

Yoshida, H., Kim, Y. H., Ozasa, H., Nagai, H., Sakamori, Y., Tsuji, T., Nomizo, T., Yasuda, Y., Funazo, T. Y., & Hirai, T. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx745 · Cited by 35 · see citing works

Vaccine immunotherapy in lung cancer: Clinical experience and future directions

Freeman-Keller, M., Goldman, J. M., & Gray, J. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.004 · Cited by 34 · see citing works

Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer

Im, J. S., Herrmann, A. C., Bernatchez, C., Haymaker, C., Molldrem, J. J., Hong, W. K., & Perez-Soler, R. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160004 · Cited by 34 · see citing works

Circulating CD8+ T-cell repertoires reveal the biological characteristics of tumors and clinical responses to chemotherapy in breast cancer patients

Lin, K.-R., Pang, D., Jin, Y., Hu, Q., Pan, Y.-M., Cui, J., Chen, X., Lin, Y.-X., Mao, X., Duan, H., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2213-1 · Cited by 34 · see citing works

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC

Liu, S., Wu, F., Li, X., Zhao, C., Jia, Y., Jia, K., Han, R., Qiao, M., Li, W., Yu, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639947 · Cited by 34 · see citing works

Depression, inflammation, and epidermal growth factor receptor (EGFR) status in metastatic non-small cell lung cancer: A pilot study

Jacobs, J. M., Traeger, L. N., Eusebio, J. R., Simon, N. M., Sequist, L. V. D., Greer, J. A., Temel, J. S., & Pirl, W. F. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.05.009 · Cited by 29 · see citing works

Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice

Jia, Y., Zhao, S., Jiang, T., Li, X., Zhao, C., Liu, Y., Han, R., Qiao, M., Liu, S., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.016 · Cited by 27 · see citing works

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial

Thress, K. S., Jacobs, V. N., Angell, H. K., Yang, J. C., Sequist, L. V. D., Blackhall, F. H., Su, W., Schüler, M., Wolf, J., Gold, K. A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.011 · Cited by 25 · see citing works

Association of CD8 T cell apoptosis and EGFR mutation in non‐small lung cancer patients

Zhao, C., Su, C., Li, X., & Zhou, C. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13504 · Cited by 23 · see citing works

The Superior Ability of Human BDCA3+ (CD141+) Dendritic Cells (DCs) to Cross-Present Antigens Derived From Necrotic Lung Cancer Cells

Gu, F., Zhang, K., Ma, L., Liu, Y., Li, C., Hu, Y., Yang, Q., Liang, J., Zeng, Y., Wang, Y., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01267 · Cited by 22 · see citing works

Immunologic and clinical implications of CD73 expression in non-small cell lung cancer (NSCLC).

Park, L. C., Rhee, K., Kim, W. B., Cho, A., Song, J., Anker, J. F., Oh, M. S., Bais, P., Namburi, S., Chuang, J. H., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.12050 · Cited by 20 · see citing works

1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations

Reck, M., Mok, T. S. K., Socinski, M. A., Jotte, R. M., Lim, W., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.1607 · Cited by 18 · see citing works

Epidermal growth factor receptor inhibition by erlotinib prevents vascular smooth muscle cell and monocyte–macrophage function in vitro

Savikko, J., Rintala, J. M. J., Rintala, S. E., & Koskinen, P. (2015) · Transplant Immunology · doi:10.1016/j.trim.2015.03.001 · Cited by 17 · see citing works

Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non–Small-cell Lung Cancer on Progression-free and Overall Survival

Jiang, T., Qiao, M., Zhou, F., Ren, S., Su, C., & Zhou, C. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.12.012 · Cited by 17 · see citing works

Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non–small cell lung cancer

Jin, S., Fang, W., Liu, X., Xing, S., Zhan, J., Ma, Y., Huang, Y., Zhou, N., Zhao, H., & Zhang, L. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s112158 · Cited by 17 · see citing works

Prospects for a personalized peptide vaccine against lung cancer

Nakahara, Y., Kouro, T., Igarashi, Y., Kawahara, M., & Sasada, T. (2019) · Expert Review of Vaccines · doi:10.1080/14760584.2019.1635461 · Cited by 15 · see citing works

Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFNα in melanoma

Khunger, A., Sarikonda, G., Tsau, J., Pahuja, A., Alfonso, Z., Gao, J., Laing, C., Vaupel, C., Dakappagari, N. K., & Tarhini, A. A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101014 · Cited by 15 · see citing works

A multi-center phase II study of toripalimab with chemotherapy in patients with EGFR mutant advanced NSCLC patients resistant to EGFR TKIs: Efficacy and biomarker analysis.

Ren, S., Zhang, J., Zhao, Y., Mu, X., Zhou, J., Bao, Z., Fan, Y., Xu, Y., Shu, Y., Guo, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.e21618 · Cited by 14 · see citing works

Phase I study of gefitinib (G) + durvalumab (D) for locally advanced/metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) sensitising mutations

Creelan, B., Yeh, T. C., Kim, S., Nogami, N., Kim, D.-W., Chow, L. Q. M., Kanda, S., Taylor, R., Tang, W., Tang, M., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz067.001 · Cited by 12 · see citing works

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations

Yang, W., Chen, N., Li, L., Chen, X., Liu, X., Zhang, Y., & Cui, J. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s262822 · Cited by 12 · see citing works

Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer

Izumi, H., Yamasaki, A., Takeda, K., Kodani, M., Touge, H., Tanaka, N., Yanai, M., Ueda, Y., Sakamoto, T., Nishii‐Ito, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.06.022 · Cited by 11 · see citing works

Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma

Gong, Z., Chen, J., Cheng, J., Sun, C., Jia, Q., Diao, X., & Zhu, B. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.03.011 · Cited by 10 · see citing works

MA19.01 Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes

Vokes, N. I., Alguilar, E. J., Adeni, A. E., Umeton, R., Sholl, L. M., Rizvi, H. A., Hellmann, M. D., Awad, M. M., & Allen, E. M. V. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.474 · Cited by 10 · see citing works

Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).

Luo, J., Bandlamudi, C., Ricciuti, B., Vokes, N. I., Schoenfeld, A. J., Egger, J. V., Sauter, J. L., Plodkowski, A. J., Preeshagul, I. R., Kris, M. G., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9549 · Cited by 10 · see citing works

Predictive value of CD73 expression in EGFR-mutation positive non-small-cell lung cancer patients received immune checkpoint inhibitors.

Ishii, H., Azuma, K., Kinoshita, T., Matsuo, N., Naito, Y., Tokito, T., Yamada, K., & Hoshino, T. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9065 · Cited by 8 · see citing works

Abstract 4981: PI3K/AKT/mTOR pathway activation drives expression of the immune inhibitory ligand PD-L1 in NSCLC.

Lastwika, K. J., Wilson, W., & Dennis, P. A. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-4981 · Cited by 7 · see citing works

Tumor Immune Microenvironment of EGFR -mutant Non-Small-Cell Lung Cancer and its Impact on Therapeutic Efficacy

Matsumoto, Y., & Koh, Y. (2020) · Immunotherapy · doi:10.2217/imt-2019-0213 · Cited by 6 · see citing works

Abstract 3181: EGFR and KRAS activation generate discrete inflammatory responses within the lung tumor microenvironment

Busch, S., Hanke, M. L., Kim, K. H., Kargl, J., & Houghton, A. M. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-3181 · Cited by 3 · see citing works

The tumor microenvironment in EGFR-driven loco-regional lung adenocarcinoma can predict higher risk of recurrence.

Khalil, M., Elkhanany, A. M., Yang, Y., Glenn, S. T., Papanicolau‐Sengos, A., Morrison, C., & Dy, G. K. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.8521 · Cited by 3 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade

Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R. M. R., Filaci, G., Coco, S., & Croce, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.799455 · Cited by 265 · see citing works

Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy

Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 237 · see citing works

The changing treatment landscape of EGFR-mutant non-small-cell lung cancer

Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00971-2 · Cited by 210 · see citing works

Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial

Jiang, T., Wang, P., Zhang, J., Zhao, Y., Zhou, J., Fan, Y., Shu, Y., Liu, X., Zhang, H., He, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00751-9 · Cited by 92 · see citing works

Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers

Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 86 · see citing works

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study

Bradley, J. D., Sugawara, S., Lee, K. H., Ostoros, G., Demirkazik, A., Zemanová, M., Sriuranpong, V., Gelatti, A. C. Z., Menezes, J. J. D., Żurawski, B. A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00036 · Cited by 86 · see citing works

Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis

Zhao, Y., He, Y., Wang, W., Cai, Q., Ge, F., Chen, Z., Zheng, J., Zhang, Y., Deng, H., Chen, Y., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00379-6 · Cited by 72 · see citing works

Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions

Garg, P., Singhal, S. S., Kulkarni, P., Horne, D. A., Malhotra, J. D., Salgia, R., & Singhal, S. S. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13144189 · Cited by 68 · see citing works

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Hou, J., Li, H., Ma, S., He, Z., Yang, S., Hao, L., Zhou, H., Zhang, Z., Han, J., Wang, L., et al. (2022) · Biomarker Research · doi:10.1186/s40364-022-00372-6 · Cited by 62 · see citing works

Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer

Kim, C. G., Kim, G., Kim, K. H., Park, S., Shin, S., Yeo, D., Shim, H. S., Yoon, H. I., Park, S. Y., Ha, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002780 · Cited by 54 · see citing works

Treatment of NSCLC after chemoimmunotherapy — are we making headway?

Reck, M., Frost, N., Peters, S., Fox, B. A., Ferrara, R., Savai, R., & Barlési, F. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01061-7 · Cited by 56 · see citing works

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer

Zeng, Y., Yu, D., Tian, W., & Wu, F. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000805 · Cited by 49 · see citing works

Tobacco Smoking-Related Mutational Signatures in Classifying Smoking-Associated and Nonsmoking-Associated NSCLC

Ernst, S. M., Mankor, J. M., van Riet, J., von der Thüsen, J. H., Dubbink, H. J., Aerts, J. G. J. V., de Langen, A. J., Smit, E. F., Dingemans, A. C., & Monkhorst, K. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.11.030 · Cited by 46 · see citing works

Progress of Nanomaterials in Photodynamic Therapy Against Tumor

Chen, L., Huang, J., Li, X., Huang, M., Zeng, S., Zheng, J., Peng, S., & Li, S. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.920162 · Cited by 39 · see citing works

Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma

Xiao, G., Li, L., Tanzhu, G., Liu, Z., Gao, X., Wan, X. H., Xiao, D., Chen, L., Xia, X., & Zhou, R. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006243 · Cited by 38 · see citing works

EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer

Huang, H., Zhu, X., Yu, Y., Li, Z., Yang, Y., Xia, L., & Lü, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05456-5 · Cited by 38 · see citing works

Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO

Wen, S., Peng, W., Chen, Y., Du, X., Xia, J., Shen, B., & Zhou, G. (2022) · BMC Cancer · doi:10.1186/s12885-022-09296-8 · Cited by 32 · see citing works

Overcoming EGFR-TKI resistance by targeting the tumor microenvironment

Zhang, J., Vokes, N. I., Li, M., Xu, J., Bai, H., Wang, J., Wang, Z., & Zhang, J. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.08.002 · Cited by 33 · see citing works

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation

Tian, T., Yu, M., Li, J., Jiang, M.-Q., Ma, D., Tang, S., Lin, Z., Chen, L., Gong, Y., Zhu, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739090 · Cited by 32 · see citing works

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China

Miao, K., Zhang, X., Wang, H., Si, X., Ni, J., Zhong, W., Zhao, J., Xu, Y., Chen, M., Pan, R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.859938 · Cited by 31 · see citing works

Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer

Li, H., Zhang, Y., Xu, Y., Huang, Z., Cheng, G., Xie, M., Zhou, Z., Yu, Y., Xi, W., & Fan, Y. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05510-4 · Cited by 30 · see citing works

Efficacy of PD ‐1/ PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China

Sheng, J., Li, H., Yu, X., Yu, S., Chen, K., Pan, G., Xie, M., Li, N., Zhou, Z., & Fan, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14171 · Cited by 28 · see citing works

m6A-mediated upregulation of lncRNA-AC026356.1 promotes cancer stem cell maintenance in lung adenocarcinoma via activating Wnt signaling pathway

Zhang, Z., Tan, X., Wu, R., Deng, T., Wang, H., Jiang, X., Zeng, P., & Tang, J. (2023) · Aging · doi:10.18632/aging.204689 · Cited by 29 · see citing works

Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects

Shi, C., Wang, Y., Xue, J., & Zhou, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940288 · Cited by 30 · see citing works

TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection

Soo, R. A., de Marinis, F., Han, J., Ho, J., Martin, E. C., Servidio, L., Sandelin, M., & Popat, S. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.09.005 · Cited by 28 · see citing works

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Wiest, N. E., Majeed, U., Seegobin, K., Zhao, Y., Lou, Y., & Manochakian, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751209 · Cited by 26 · see citing works

CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr -Mutant Lung Cancer

Nishii, K., Ohashi, K., Tomida, S., Nakasuka, T., Hirabae, A., Okawa, S., Nishimura, J., Higo, H., Watanabe, H., Kano, H., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0751 · Cited by 26 · see citing works

Exosome-Based Liquid Biopsy in Early Screening and Diagnosis of Cancers

Hao, X., Liu, Z., Ma, F., Li, T., Liu, C., Wang, N., Guan, J., He, N., Liu, J., Lu, S., et al. (2025) · Dose-Response · doi:10.1177/15593258251344480 · Cited by 24 · see citing works

Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management

Borgeaud, M., Olivier, T., Bar, J., Saw, S. P. L., Parikh, K., Banna, G. L., Vito, C. D., Feldman, J., Le, X., & Addeo, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70024 · Cited by 26 · see citing works

Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma

Li, F., Wu, H., Du, X., Sun, Y., Rausseo, B. N., Talukder, A. H., Katailiha, A. S., Elzohary, L., Wang, Y., Wang, Z., et al. (2023) · Vaccines · doi:10.3390/vaccines11091460 · Cited by 23 · see citing works

Frizzled‐7‐targeting antibody (SHH002‐hu1) potently suppresses non–small‐cell lung cancer via Wnt/β‐catenin signaling

Li, K., Mao, S., Li, X., Zhao, H., Wang, J., Wang, C., Wu, L., Zhang, K., Yang, H., Jin, M., et al. (2023) · Cancer Science · doi:10.1111/cas.15721 · Cited by 20 · see citing works

EGFR-mutant NSCLC may remodel TME from non-inflamed to inflamed through acquiring resistance to EGFR-TKI treatment

Chen, Q., Xia, L., Wang, J., Zhu, S., Wang, J., Li, X., Yu, Y., Li, Z., Wang, Y., Zhu, G., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107815 · Cited by 18 · see citing works

Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond

Vathiotis, I. A., Bafaloukos, D. I., Syrigos, K. N., & Samonis, G. (2023) · Cancers · doi:10.3390/cancers15041286 · Cited by 18 · see citing works

miR-4739 promotes epithelial-mesenchymal transition and angiogenesis in “driver gene-negative” non-small cell lung cancer via activating the Wnt/β-catenin signaling

Cen, W., Yan, Q., Zhou, W., Mao, M., Huang, Q., Lin, Y., & Jiang, N. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00848-z · Cited by 17 · see citing works

Targeted Degradation of EGFR Mutations via Self-Delivery Nano-PROTACs for Boosting Tumor Synergistic Immunotherapy

Wang, X., Yan, J., Zhao, Y., Li, S., Ma, Z., Duan, X., Wang, Y., Jiao, J., Gu, C., & Zhang, G. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c01103 · Cited by 17 · see citing works

Landscape of adenosine pathway and immune checkpoint dual blockade in NSCLC: progress in basic research and clinical application

Wang, R.-L., Liu, Z., Wang, T., Zhang, J., Liu, J., & Zhou, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1320244 · Cited by 16 · see citing works

Identification of the ferroptosis-related long non-coding RNAs signature to improve the prognosis prediction and immunotherapy response in patients with NSCLC

Li, M., Zhang, Y., Fan, M., Ren, H. J., Chen, M., & Shi, P. (2021) · BMC Medical Genomics · doi:10.1186/s12920-021-01133-4 · Cited by 15 · see citing works

Comprehensive analysis of PD-L1 expression, tumor-infiltrating lymphocytes, and tumor microenvironment in LUAD: differences between Asians and Caucasians

Bie, F., Tian, H., Sun, N., Zang, R., Zhang, M., Song, P., Liu, L., Peng, Y., Bai, G., Zhou, B., et al. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01221-3 · Cited by 15 · see citing works

Comprehensive characterization of posttranscriptional impairment-related 3′-UTR mutations in 2413 whole genomes of cancer patients

Wei, W., Gao, W., Li, Q., Liu, Y., Chen, H., Cui, Y., Sun, Z. S., & Liu, Z. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00305-0 · Cited by 15 · see citing works

Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer

Wang, Y., Huang, S., Feng, X., Xu, W., Luo, R., Zhu, Z., Zeng, Q., & He, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145128 · Cited by 15 · see citing works

Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage III non-small-cell lung cancer: a retrospective cohort study

Zhao, G., Zhang, H., Xu, F., Lu, C., Zhu, Q., Grossi, F., Divisi, D., Ma, T., Gu, J., & Ge, D. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-871 · Cited by 14 · see citing works

The Real-world Therapeutic Analysis of First-line Immunotherapy in Chinese Patients with Drive Gene Positive for Advanced Non-Small Cell Lung Cancer

Liu, L., Li, F., Zhao, J., Zhuo, X., Lai, J., Wang, J., Jiang, F., Xu, W., Luan, F., Lin, X., et al. (2023) · Journal of Cancer · doi:10.7150/jca.77199 · Cited by 15 · see citing works

Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics

Ritu, R., Chandra, P., & Das, A. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01201-2 · Cited by 15 · see citing works

Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review

Dong, Y., Khan, L., & Yao, Y. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.06.004 · Cited by 14 · see citing works

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer

Lei, S., Xu, H., Li, H., Yang, Y., Xu, F., Li, J., Wang, Z., Xing, P., Hao, X., & Wang, Y. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15021 · Cited by 13 · see citing works

Sintilimab plus anlotinib as second‐ or third‐line therapy in metastatic non‐small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single‐arm, phase II trial

Chen, K., Xu, Y., Huang, Z., Yu, X., Hong, W., Li, H., Xu, X., Lu, H., Xie, F., Chen, J., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6548 · Cited by 12 · see citing works

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy

Chen, P., Yang, Q., Li, Y., Jing, X., & Chen, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894656 · Cited by 13 · see citing works

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy

Sayer, M. R., Mambetsariev, I., Lu, K., Wong, C. W., Duche, A., Beuttler, R., Fricke, J., Pharoan, R., Arvanitis, L. D., Eftekhari, Z., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1064169 · Cited by 13 · see citing works

Therapies Targeting Immune Cells in Tumor Microenvironment for Non-Small Cell Lung Cancer

Ye, W., Li, M., & Luo, K.-W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071788 · Cited by 13 · see citing works

Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer

Qiao, M., Zhou, F., Liu, X., Jiang, T., Wang, H., Jia, Y., Li, X., Zhao, C., Cheng, L., Chen, X., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005436 · Cited by 12 · see citing works

Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR -Mutant Non–Small Cell Lung Cancer

Wang, S., Lai, J.-C., Li, Y., Tang, C., Lu, J., Han, M. S., Ye, X., Jia, L., Cui, W., Yang, J., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1817 · Cited by 12 · see citing works

Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors

Chen, Q., Shang, X., Liu, G., Ma, X., Han, W., Wang, X., & Liu, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931718 · Cited by 12 · see citing works

NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma

Ning, Y., Lin, K., Liu, X., Ding, Y., Jiang, X. W., Zhang, Z., Xuan, Y.-T., Dong, L., Liu, L., Wang, F., et al. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02475-8 · Cited by 12 · see citing works

What Is New in Biomarker Testing at Diagnosis of Advanced Non-Squamous Non-Small Cell Lung Carcinoma? Implications for Cytology and Liquid Biopsy

Hofman, P. M. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2020015 · Cited by 12 · see citing works

First-Line Osimertinib in Patients With EGFR-Mutated Non-Small Cell Lung Cancer: Effectiveness, Resistance Mechanisms, and Prognosis of Different Subsequent Treatments

Nie, N., Li, J., Zhang, J., Dai, J., Liu, Z., Ding, Z., Wang, Y., Zhu, M., Hu, C., Han, R., et al. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221134735 · Cited by 11 · see citing works

Immunotherapy-based therapy as a promising treatment for EGFR-mutant advanced non-small cell lung cancer patients after EGFR-TKI resistance

Ding, J., Ding, X., & Leng, Z. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2170879 · Cited by 11 · see citing works

Integrated analysis of EGFR mutated non‐small cell lung cancer reveals two distinct molecular subtypes

Bai, M., Wu, L., Zhao, M., Jin, P., Liu, J., Wang, W., Gao, X., Wang, Y., Chong, W., Yu, J., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1431 · Cited by 11 · see citing works

Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation

Cheng, Y., Yang, B., Ouyang, W., Chen, J., Zhang, W., Chen, G., Zhang, J., Yu, J., & Xie, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.920047 · Cited by 11 · see citing works

Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen

Liu, K.-J., Li, H., Tan, Q.-Q., Jiang, T., Peng, K., Chen, H.-J., Zhou, Q., Zhang, X., Zheng, Z., Chen, S., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107933 · Cited by 10 · see citing works

Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis

Hu, Y., Liu, S., Wang, L., Liu, Y., Zhang, D., & Zhao, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1202822 · Cited by 10 · see citing works

PD-L2 drives resistance to EGFR-TKIs: dynamic changes of the tumor immune environment and targeted therapy

Wang, S., Su, D., Chen, H., Lai, J.-C., Tang, C., Yu, L., Wang, Y., Yang, Y., Qin, M., Jia, L., et al. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01317-2 · Cited by 10 · see citing works

A Novel Integrated Metabolism-Immunity Gene Expression Model Predicts the Prognosis of Lung Adenocarcinoma Patients

Chen, S., Duan, Y., Wu, Y., Yang, D., & An, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.728368 · Cited by 10 · see citing works

ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma

Zhang, W., Shang, X., Liu, G., Ma, X., Yang, R. R., Xia, H., Zhang, Y., Zheng, Q., Wang, X., & Liu, Y. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-022-02279-2 · Cited by 9 · see citing works

Decoding temporal heterogeneity in NSCLC through machine learning and prognostic model construction

Cheng, J., Xiao, M., Meng, Q., Zhang, M., Zhang, D., Liu, L., Jin, Q., Fu, Z., Li, Y., Chen, X., et al. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-024-03435-0 · Cited by 9 · see citing works

Multimodal omics analysis of the EGFR signaling pathway in non-small cell lung cancer and emerging therapeutic strategies

Li, Y. L., YU, L., ZHOU, S., Zhou, H., & Wu, Q. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.059311 · Cited by 10 · see citing works

Durvalumab after chemoradiotherapy in non‐small cell lung cancer with EGFR mutation: A real‐world study ( HOT2101 )

Tsuji, K., Mizugaki, H., Yokoo, K., Kobayashi, M., Kawashima, Y., Kimura, N., Yokouchi, H., Kikuchi, H., Sumi, T., Kawai, Y., et al. (2024) · Cancer Science · doi:10.1111/cas.16094 · Cited by 8 · see citing works

Research trends in lung cancer and the tumor microenvironment: a bibliometric analysis of studies published from 2014 to 2023

Huang, Z., Xie, T., Xie, W., Chen, Z., Wen, Z., & Yang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1428018 · Cited by 8 · see citing works

Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells

Nakagawa, N., Miyake, N., Ochi, N., Yamane, H., Takeyama, M., Nagasaki, Y., Ikeda, T., Yokota, E., Fukazawa, T., Nakanishi, H., et al. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112940 · Cited by 8 · see citing works

Prediction of EGFR mutation status and its subtypes in non-small cell lung cancer based on 18F-FDG PET/CT radiological features

Fan, Y., Liu, Y., Ouyang, X., Su, J., Zhou, X., Jia, Q., Chen, W., Chen, W., & Liu, X. (2025) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001948 · Cited by 7 · see citing works

Cell Death, Molecular Targeted Therapies, and Metabolic Reprogramming in EGFR-Mutant Lung Cancer

Joshi, H., & Sheikh, M. S. (2025) · Cancers · doi:10.3390/cancers17172791 · Cited by 7 · see citing works

From gene editing to tumor eradication: The CRISPR revolution in cancer therapy

Ali, A., Azmat, U., Khatoon, A., Akbar, K., Murtaza, B., Ji, Z., Irshad, U., & Su, Z. (2025) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2025.04.003 · Cited by 7 · see citing works

Integration of single-cell and bulk RNA-seq to establish a predictive signature based on the differentiation trajectory of M2 macrophages in lung adenocarcinoma

Chen, Z., Yang, J., Li, Y., Zeng, W., Bai, Y., Ding, C., Xu, C., Li, C., Chen, J., Ju, S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1010440 · Cited by 7 · see citing works

Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)

Choi, D.-H., Jung, H. A., Park, S., Sun, J., Ahn, J. S., Ahn, M., & Lee, S. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-643 · Cited by 7 · see citing works

Comprehensive Analysis of HMCN1 Somatic Mutation in Clear Cell Renal Cell Carcinoma

Gong, Z., Wu, X., Guo, Q., Du, H., Zhang, F., & Kong, Y. (2022) · Genes · doi:10.3390/genes13071282 · Cited by 7 · see citing works

Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors

Nakagawa, N., & Kawakami, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.952393 · Cited by 7 · see citing works

Hyperthermia‐induced cytotoxicity and modulation of PD‐L1 and MHC‐I expression in human non‐small cell lung cancer cell lines

Tu, Y., Yeh, W., Fang, Y., Lo, K., Liang, L., Liu, X.-C., Tsai, C., Cheng, C., Lin, M., Yu, H., et al. (2025) · Experimental Physiology · doi:10.1113/ep092791 · Cited by 6 · see citing works

SNHG16-loaded extracellular vesicles from hypoxic NSCLC cells drive M2 macrophage polarization to enhance cancer aggressiveness

Hou, Y., Li, X., Zeng, L., & Zhang, Y. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.08.022 · Cited by 6 · see citing works

Overcoming EGFR‐Mediated Dendritic Cell Dysfunction to Enhance Anti‐tumor Immunity in EGFR‐Mutant NSCLC by Precisely Targeting CD73 With pH‐responsive Nanocarriers

Shang, X., Geng, X., Wang, Z., Yuan, S., Ding, S., Liu, G., Ma, X., Sun, X., Wang, H., Sun, Y. H., et al. (2025) · Advanced Science · doi:10.1002/advs.202513182 · Cited by 6 · see citing works

Immunotherapy in EGFR-mutant non-small cell lung cancer

Wang, L., Xian, X., Ke, H., & Wang, K. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01927-1 · Cited by 7 · see citing works

Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study

Kuribayashi, T., Ohashi, K., Nishii, K., Ninomiya, K., Tsubata, Y., Ishikawa, N., Kodani, M., Kanaji, N., Yamasaki, M., Fujitaka, K., et al. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05618-4 · Cited by 6 · see citing works

Chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations (2023 edition)

Hao, X., The Society of Cancer Precision Medicine of Chinese Anti-Cancer Association, & The Lung Cancer Expert Group of Chinese Medical Association Publishing House (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003055 · Cited by 6 · see citing works

Pan-Cancer Landscape of NEIL3 in Tumor Microenvironment: A Promising Predictor for Chemotherapy and Immunotherapy

Liao, W., Huang, S., Lin, L., Wang, J., Li, J., Chen, Y., Chen, L., Lian, Y., & Huang, Y. (2022) · Cancers · doi:10.3390/cancers15010109 · Cited by 6 · see citing works

Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR‐TKI in non–small cell lung cancer patients with EGFR mutation: A multicenter retrospective study

Hata, T., Sakaguchi, C., Hirano, K., Kobe, H., Ishida, M., Nakano, T., Tachibana, Y., Tamiya, N., Shiotsu, S., Takeda, T., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.14836 · Cited by 6 · see citing works

Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance

Li, Y., Jiang, H., Qian, F., Chen, Y., Zhou, W., Zhang, Y., Lü, J., Lou, Y., Han, B., & Zhang, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161718 · Cited by 6 · see citing works

Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion

Patel, S. P., & Patel, J. D. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02680-1 · Cited by 6 · see citing works

Remarkable response to third-generation EGFR-TKI plus crizotinib in a patient with pulmonary adenocarcinoma harboring EGFR and ROS1 co-mutation: a case report

Wu, Z., Zhang, Z., Zhang, D., & Li, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357230 · Cited by 6 · see citing works

Low-exhaustion peripheral circulating γδ T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study

Zhang, D., Liu, G., Ye, J., Li, K., Zhang, G., Quan, Q., Zhu, X., & Peng, L. (2025) · BMC Cancer · doi:10.1186/s12885-025-13497-2 · Cited by 5 · see citing works

Targeting IL-6/STAT3 signaling to mitigate sarcopenia: Insights from immuno-metabolic crosstalk in NSCLC

Kumar, G., Khandibharad, S., & Singh, S. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152727 · Cited by 5 · see citing works

An effective prognostic model for assessing prognosis of non-small cell lung cancer with brain metastases

Wang, R., Zhang, X. Y., He, C., & Guo, W. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1156322 · Cited by 5 · see citing works

Implication of PD‑L1 polymorphisms rs2297136 on clinical outcomes of patients with advanced NSCLC who received PD‑1 blockades: A retrospective exploratory study

Gong, Q., Qie, H., Dong, S.-Y., & Jiang, H. (2024) · Oncology Letters · doi:10.3892/ol.2024.14277 · Cited by 5 · see citing works

Evaluation of EGFR-TKIs and ICIs treatment stratification in non-small cell lung cancer using an encrypted multidimensional radiomics approach

Zhang, X., Qiu, X., Zhang, Y., Lai, Q., Zhang, G., & Zhang, G. (2025) · Cancer Imaging · doi:10.1186/s40644-025-00824-w · Cited by 5 · see citing works

EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?

Hofman, P. M. (2021) · Cells · doi:10.3390/cells10082157 · Cited by 5 · see citing works

Comprehensive Exploration of Tumor Microenvironment Modulation Based on the ESTIMATE Algorithm in Bladder Urothelial Carcinoma Microenvironment

Chen, J., Lv, B., Zhan, Y., Zhu, K., Zhang, R., Chen, B., Jin, Y., Li, Y., Zheng, J., & Lin, C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.724261 · Cited by 5 · see citing works

A retrospective real-world study: the efficacy of immune-related combination therapies in advanced non-small cell lung cancer after resistance to EGFR-TKIs

Cai, R., Liu, Y., Yu, M., Sha, H., Guo, M., Chen, Y., Ye, J., Zhou, G., Fang, Y., & Shen, B. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03570-9 · Cited by 5 · see citing works

HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer

González‐Cao, M., Cai, X., Bracht, J. W. P., Han, X., Yang, Y., Pedraz‐Valdunciel, C., Morán, T., García-Corbacho, J., Aguilar, A., Bernabé, R., et al. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s455034 · Cited by 5 · see citing works

The Nail in the Coffin?: Examining the KEYNOTE-789 Clinical Trial’s Impact

Arter, Z., & Nagasaka, M. (2024) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s443099 · Cited by 5 · see citing works

Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis

Zhu, L., He, W., Xie, C., Yang, S., Zhang, C., & Zhu, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512468 · Cited by 4 · see citing works

Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis

Fujisaki, T., Miyauchi, E., Kida, G., Miura, Y., Watanabe, K., Ashinuma, H., Tamiya, M., Kikuchi, H., Arai, D., Takahashi, S., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108597 · Cited by 4 · see citing works

The Prognostic Role of Tertiary Lymphoid Structures and Immune Microenvironment Signatures in Early-Stage EGFR-Mutant Lung Adenocarcinoma

Hsu, W.-H., Hsu, C., Hsieh, M., & Yang, J. C. (2025) · Cancers · doi:10.3390/cancers17142379 · Cited by 4 · see citing works

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLC

Zhu, P., Li, Z., Sun, Y., Liu, T., & Yin, R. H. (2024) · Cancer Science · doi:10.1111/cas.16428 · Cited by 10 · see citing works

It might be a dead end: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC

Akao, K., Oya, Y., Sato, T., Ikeda, A., Horiguchi, T., Gotô, Y., Hashimoto, N., Kondo, M., & Imaizumi, K. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00251 · Cited by 6 · see citing works

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation

Ma, L., Diao, B., Huang, Z., Wang, B., Yu, J., & Meng, X. (2021) · 癌症：英文版 · doi:10.1002/cac2.12229 · Cited by 33 · see citing works

[Progress of Immunotherapy in EGFR-mutated Advanced Non-small Cell Lung Cancer].

Liu, Y., & Miao, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.106.26 · Cited by 2 · see citing works

Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancer

Azuma, K., Osuga, M., Itoh, S., Kawa, Y., Kozuki, T., Toi, Y., Murotani, K., Izumi, M., Murata, D., Hata, A., et al. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101127